Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns "Outperform" Rating from Wedbush

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report)'s stock had its "outperform" rating reiterated by investment analysts at Wedbush in a research note issued to investors on Tuesday, RTT News reports. They presently have a $30.00 price objective on the stock, up from their previous price objective of $28.00. Wedbush's price target would suggest a potential upside of 60.17% from the stock's current price.

Separately, TheStreet upgraded Kiniksa Pharmaceuticals from a "d+" rating to a "c" rating in a report on Thursday, February 29th.

Kiniksa Pharmaceuticals Stock Down 4.9 %

KNSA traded down $0.97 during trading on Tuesday, hitting $18.73. The company's stock had a trading volume of 425,682 shares, compared to its average volume of 411,909. The firm's 50 day moving average price is $19.72 and its two-hundred day moving average price is $17.93. Kiniksa Pharmaceuticals has a 12 month low of $10.29 and a 12 month high of $22.09. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of 104.06 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.15. The firm had revenue of $83.40 million during the quarter, compared to the consensus estimate of $72.31 million. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%. On average, sell-side analysts forecast that Kiniksa Pharmaceuticals will post -0.05 earnings per share for the current year.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, CFO Mark Ragosa sold 12,000 shares of the company's stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $20.00, for a total transaction of $240,000.00. Following the completion of the transaction, the chief financial officer now directly owns 15,632 shares of the company's stock, valued at $312,640. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CAO Michael R. Megna sold 5,126 shares of the company's stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the sale, the chief accounting officer now owns 17,588 shares in the company, valued at $383,242.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 12,000 shares of the company's stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $20.00, for a total value of $240,000.00. Following the sale, the chief financial officer now owns 15,632 shares in the company, valued at approximately $312,640. The disclosure for this sale can be found here. Insiders sold 45,109 shares of company stock valued at $949,929 over the last three months. Company insiders own 54.23% of the company's stock.

Institutional Trading of Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Virtus ETF Advisers LLC raised its stake in Kiniksa Pharmaceuticals by 3.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 19,132 shares of the company's stock valued at $336,000 after buying an additional 671 shares during the period. Legal & General Group Plc raised its stake in Kiniksa Pharmaceuticals by 7.8% in the fourth quarter. Legal & General Group Plc now owns 11,712 shares of the company's stock valued at $175,000 after buying an additional 850 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Kiniksa Pharmaceuticals by 0.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 205,557 shares of the company's stock worth $3,079,000 after purchasing an additional 1,057 shares during the period. Tejara Capital Ltd increased its stake in shares of Kiniksa Pharmaceuticals by 3.2% during the third quarter. Tejara Capital Ltd now owns 35,000 shares of the company's stock worth $608,000 after purchasing an additional 1,069 shares during the period. Finally, Royal Bank of Canada increased its stake in shares of Kiniksa Pharmaceuticals by 44.2% during the second quarter. Royal Bank of Canada now owns 3,523 shares of the company's stock worth $50,000 after purchasing an additional 1,080 shares during the period. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.